[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356292-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356292-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","combining-sorafenib-with-spermine-and-sphingosine-synergistically-enhances-anticancer-efficacy-by-modulating-metabolic-pathways-and-gut-microbiome-in-hepatocellular-carcinoma","Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma","","Hepatocellular carcinoma (HCC) accounts for about 90% of liver cancer and remains a major cause of cancer mortality. This study tests whether microbial metabolites can potentiate sorafenib, a first-line multi-kinase inhibitor for advanced HCC. A metabolite-library screen identified spermine and sphingosine that synergistically suppress tumor growth in cultured HCC cells, patient-derived organoids, and a xenograft model. Mechanistically, spermine induces S-phase arrest, while sphingosine with sorafenib promotes G1 arrest, apoptosis, and changes in metabolic enzyme expression, alongside gut microbiome remodeling with a Faecalibaculum shift.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/combining-sorafenib-with-spermine-and-sphingosine-synergistically-enhances-anticancer-efficacy-by-modulating-metabolic-pathways-and-gut-microbiome-in-hepatocellular-carcinoma/356292/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/combining-sorafenib-with-spermine-and-sphingosine-synergistically-enhances-anticancer-efficacy-by-modulating-metabolic-pathways-and-gut-microbiome-in-hepatocellular-carcinoma/356292.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were spermine and sphingosine identified in the study?","Question",{"text":63,"@type":64},"Through a screen of a microbiome metabolite library, the study identified spermine and sphingosine as candidates that enhance sorafenib’s anticancer effects in HCC cell models.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What anti-tumor effects did the combination show across models?",{"text":68,"@type":64},"The combination of sorafenib with spermine or sphingosine suppressed tumor growth in cultured HCC cells, patients-derived HCC organoids, and a xenograft mouse model.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism explains the synergy between sorafenib and the metabolites?",{"text":72,"@type":64},"Spermine triggered S-phase cell-cycle arrest, while sphingosine and sorafenib induced G1 arrest. Together, these changes increased the sub-G1 population and promoted apoptosis, alongside altered expression of metabolic enzymes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356292,1790152243,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Ivyspring  \nInternational Publisher  \nInternationalJournal of Biological Sciences  \n2026; 22(3): 1082-1102. doi: 10.7150/ijbs.118753  \nResearch Paper  \nCombining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma  \nHay-Ran Jang1*, Hyun-Jin Kim1*, Bo-Young Kim1, Jae-Hoon Jeong2, Jeon-Kyung Kim2, Jin Ah Won1,3, Hye Hyun Yoo1,3, Yong Gu Lee1,3, and Hyungshin Yim1,3􀀍  \n1. Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan, Republic of Korea.  \n2. School of Pharmacy, Institute of New Drug Development, Jeonbuk National University, Jeonju, Republic of Korea.  \n3. Pharmacomicrobiomics Research Center, College of Pharmacy, Hanyang University, Ansan, Republic of Korea.  \n* These authors contributed equally.  \n􀀍 Corresponding author: Hyungshin Yim, E-[mail: hsyim@hanyang.ac.kr](mail: hsyim@hanyang.ac.kr); Phone: +82-31-400-5810; Fax: +82-31-400-5958.  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.06.03; Accepted: 2025.12.13; Published: 2026.01.01  \nAbstract  \nHepatocellular carcinoma (HCC), which makes up about 90% of liver cancer, is the third leading cause of cancer-related death. Recent studies suggest that metabolites derived from the gut microbiome may offer new therapeutic opportunities for HCC. In this study, we explored whether microbial metabolites could enhance the effectiveness of sorafenib, a first-line multi-kinase inhibitor used in advanced HCC. Through a screen of a microbiome metabolite library, we identified spermine and sphingosine as potential candidates that boosted anticancer effects of sorafenib in HepG2, Huh7, and SK-Hep-1 cells. These metabolites worked synergistically with sorafenib to suppress tumor growth in cultured HCC cells, patients-derived HCC organoids, and a xenograft mouse model. Mechanistically, spermine triggered cell cycle arrest at the S phase, while sphingosine and sorafenib induced G1 arrest, contributing to an increased sub-G1 population and apoptosis when combined. Notably, sorafenib treatment led to the downregulation of SMOX (a key catabolic enzyme for spermine), as well as SPHK1 and CERS1 (critical enzymes involved in sphingosine metabolism), whose high expression levels are associated with poorer survival outcomes in liver cancer patients according to TCGA data. A 16S rRNA sequencing analysis revealed that combination of sorafenib with spermine or sphingosine alters the gut microbiome, increasing the relative abundance of Faecalibaculum, inversely correlated with tumor sizes in a xenograft mouse model. Therefore, we propose that combining sorafenib with spermine or sphingosine could enhance its anti-HCC effects by promoting apoptosis and reducing the expression of metabolic enzymes. Moreover, Faecalibaculum may serve as a potential microbiome-based prognostic marker for HCC.  \nKeywords: spermine, sphingosine, microbiome metabolite, sorafenib, liver cancer  \n1. Introduction  \nLiver cancer is the third most common cause of cancer-related death worldwide in 2022 accounting for 7.8% of all cancer deaths [1] . Hepatocellular carcinoma (HCC) is the most common liver cancer accounting for approximately 90% [2] . It usually develops with chronic liver disease and requires a complex, multidisciplinary treatment, because its development is driven by various primary  \ncarcinogens, including hepatitis B or C virus, metabolic disorders, alcohol consumption, and gene mutation [3-5] . In systemic chemotherapy, sorafenib, a multi-kinase inhibitor targeting VEGFR, PDGFR, and RAF/MAPK, is the standard first-line treatment for HCC patients [3-5] . Another multi-kinase inhibitor, lenvatinib, has demonst","cbCair6SYQTxKyx8","https://ap.wps.com/l/cbCair6SYQTxKyx8","pdf",11604323,21,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Global burden and biology of HCC\n## Current systemic therapies and resistance\n## Emerging role of gut microbiome in HCC","[{\"question\":\"How were spermine and sphingosine identified in the study?\",\"answer\":\"Through a screen of a microbiome metabolite library, the study identified spermine and sphingosine as candidates that enhance sorafenib’s anticancer effects in HCC cell models.\"},{\"question\":\"What anti-tumor effects did the combination show across models?\",\"answer\":\"The combination of sorafenib with spermine or sphingosine suppressed tumor growth in cultured HCC cells, patients-derived HCC organoids, and a xenograft mouse model.\"},{\"question\":\"What mechanism explains the synergy between sorafenib and the metabolites?\",\"answer\":\"Spermine triggered S-phase cell-cycle arrest, while sphingosine and sorafenib induced G1 arrest. Together, these changes increased the sub-G1 population and promoted apoptosis, alongside altered expression of metabolic enzymes.\"}]","Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma | PDF",1790124453,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68600074934fc41c01ab5c7fbd20f154.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a1dbb882eb608c5ac5c555392ec91d3.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09e7a842017ec25d44e671e5871d2ba2.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0aa5db3034bcc3bc2611a09b28246de0.webp",980,1268]